The roles of FLT3 in hematopoiesis and leukemia

Blood

Volumn 100, Issue 5, 2002, Pages 1532-1542

  Gary Gilliland, D ^a,b   Griffin, James D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; FLT3 LIGAND; GROWTH FACTOR; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CELL MATURATION; CELL PROLIFERATION; DENDRITIC CELL; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; IMMUNE SYSTEM; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEM CELL; STROMA CELL;

EID: 0036720398     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0492     Document Type: Review

References (152)

1. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
2. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations
3. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family
4. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene
5. Hematopoietic receptors of class III receptor-type tyrosine kinases
6. Genomic structure of the downstream part of the human FLT3 gene: Exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III
7. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells
8. Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues
9. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase
10. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene
11. Expression of the flt3 receptor and its ligand on hematopoietic cells
12. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
13. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells
14. The flt3/flk-2 ligand: Receptor distribution and action on murine haemopoietic cell survival and proliferation
15. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells
16. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors
17. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells
18. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
19. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots
20. Structural analysis of human and murine flt3 ligand genomic loci
21. Flt3-ligand production by human bone marrow stromal cells
22. The flt3 ligand: A hematopoietic stem cell factor whose activities are distinct from steel factor
23. Synergistic action of Flt3 and gp130 signalings in human hematopoiesis
24. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapplng yet distinct activities
25. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7
26. Biology of flt3 ligand and receptor
27. + blood progenitors expressing different levels of c-kit protein
28. Haematopoietic action of flt3 ligand on cord blood-derived CD34-positive cells expressing different levels of flt3 or c-kit tyrosine kinase receptor: Comparison with stem cell factor
29. + bone marrow progenitor cells in vitro
30. + hematopoietic progenitor cells
31. Hematologic effects of flt3 ligand in vivo in mice
32. In vivo generation of human dendritic cell subsets by Flt3 ligand
33. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells
34. Isolation and characterization of primitive hematopoietic progenitors of murine fetal liver
35. Regulation of colony forming cell generation by flt-3 ligand
36. Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability
37. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors
38. Administration of Flk2/Flt3 ligand induces expansion of human high-proliferative potential colony-forming cells in the SCID-hu mouse
39. - dendritic cell precursors
40. FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units
41. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells
42. flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors
43. The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis
44. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells
45. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
46. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15
47. In vivo effects of flt3 ligand
48. FLT3: Receptor and ligand: Biology and potential clinical application
49. Biologic effects and potential clinical applications of Flt3 ligand
50. Biology and potential clinical applications of flt3 ligand
51. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
52. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model
53. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma
54. Antileukemic activity of Flt3 ligand in murine leukemia
55. Acute leukemia in adults
56. Effects of human FLT3 ligand on myeloid leukemia cell growth: Heterogeneity in response and synergy with other hematopoietic growth factors
57. Effects of FLT3 ligand on human leukemia cells, I: Proliferative response of myeloid leukemia cells
58. Effects of Flt3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells
59. Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children
60. Retroviral mediated gene transfer of Flt3 ligand enhances proliferation and MAP kinase activity of AML5 cells
61. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells
62. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: Regulation of Bcl-2 and Bax
63. Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis
64. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells
65. p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosinephosphoryiated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells
66. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells
67. Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells
68. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor
69. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase
70. Analysis of the mitogenic pathway of the FLT3 receptor and characterization in its C terminal region of a specific binding site for the PI3' kinase
71. Phosphatidylinositol-3′ kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase
72. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphoryfated substrates
73. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase
74. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
75. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
76. The expression of FMS, KIT and FLT3 in hematopoietic malignancies
77. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
78. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts
79. Expression of the FLT3 gene in human leukemia-lymphoma cell lines
80. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines
81. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
82. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myeiodysplasía
83. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia
84. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series of patients and cell lines
85. Internal tandem duplication in the juxtatransmembrane domain of the flt3 is not involved in blastic crisis of chronic myeloid leukemia
86. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
87. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeioid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
88. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia
89. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
90. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
91. Chromosome and molecular abnormalities in myelodysplastic syndromes
92. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia
93. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia
94. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
95. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
96. Molecular evolution of acute myeloid leukaemia in relapse: Unstable N-ras and FLT3 genes compared with p53 gene
97. FLT3 mutations studies and clinical correlates of c-kit D816 mutation in adult systemic mast cell disease
98. FLT3 is not frequently mutated in solid tumors
99. High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells
100. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12-trials
101. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the Internal tandem duplication of FLT3: A cancer and leukemia group B study
102. Point mutations in the FLT3 gene in AML
103. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
104. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region
105. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors
106. The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization
107. Theme and variations: Juxtamembrane regulation of receptor protein kinases
108. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface
109. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation
110. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase
111. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism
112. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
113. Switching signals on or off by receptor dimerization
114. Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: Insights into kinase mechanism
115. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
116. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
117. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
118. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
119. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
120. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
121. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model
122. Analysis of FLT3-activating mutations in 713 patients with acute myelogenous leukemia (AML): High prevalence in FAB-subtype M5 and identification of subgroups with poor prognosis [abstract]
123. FLT3 internal tandem duplications and survival in adult acute myeloid leukemia: Analysis of 188 intensively treated patients
124. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
125. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
126. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
127. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy
128. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
129. FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts in vitro and in vivo
130. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
131. SUGEN compounds SU5416 and SU11248 inhibit Flt3 activity: Therapeutic application in AML
132. SU5416 and SU5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells
133. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
134. Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia
135. D835 mutations are commonly associated with other molecular lesions in adult AML
136. The fusion gene Cbfβ blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukemia
137. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
138. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription and blocks granulocytic differentiation
139. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
140. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11
141. Molecular genetics of acute myeloid leukaemia
142. Hematologic malignancies
143. High incidence of FLT3/ITD in childhood APL
144. C-kit mutations in core binding factor leukemias
145. c-kit protooncogene exon 8 in-frame deletion plus Insertion mutations in acute myeloid leukaemla
146. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
147. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
148. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
149. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
150. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia
151. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
152. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model